Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

Phio touts Phase 1b progress for PH-762 but reveals no trial data or near-term catalysts.

What the company is saying

Phio Pharmaceuticals Corp. is highlighting the completion and presentation of Phase 1b clinical trial results for its lead compound, PH-762, at the 2026 Annual Meeting of the American Society for Dermatologic Surgery. The company frames PH-762 as a differentiated, tissue-sparing neoadjuvant therapy with the potential to shrink tumors before surgery and improve outcomes for patients with cutaneous carcinomas. Robert Bitterman, President and CEO, emphasizes the growing body of clinical evidence and positions PH-762 as addressing an unmet need in skin cancer treatment. The announcement stresses that PH-762 was well-tolerated in the Phase 1b trial and may serve as a non-surgical alternative to current standards such as Mohs micrographic surgery. The company also notes that John Strasswimmer, M.D., Ph.D., served as the lead investigator and presented the findings. While the tone is optimistic and forward-looking, the release does not provide any quantitative safety, efficacy, or outcome data from the trial. The narrative is built around potential and planned next steps, specifically a Phase 2b study in the first half of 2027.

What the data suggests

The only hard data disclosed are the completion and presentation of a Phase 1b trial (NCT# 06014086) for PH-762, with the trial evaluating the compound in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The company claims PH-762 is well-tolerated and may be tissue-sparing, but no numerical results, response rates, adverse event frequencies, or comparative efficacy figures are provided. The announcement confirms that additional studies are needed and that a Phase 2b trial is planned for the first half of 2027, indicating that the program remains in early clinical development. No financial, operational, or period-over-period metrics are disclosed, and there is no evidence presented to support claims of clinical benefit or differentiation versus standard of care. The gap between the promotional narrative and actual disclosed evidence is significant, with all efficacy and safety claims remaining unsubstantiated by data in this release.

Analysis

The announcement presents the completion and conference presentation of a Phase 1b clinical trial for PH-762, emphasizing its potential as a non-surgical, tissue-sparing therapy for skin cancers. However, the release does not disclose any quantitative safety or efficacy data, nor does it provide concrete evidence of clinical benefit beyond general statements of tolerability and potential. Most key claims are forward-looking, focusing on what PH-762 'may' achieve or its 'potential' impact, and the next clinical milestone (Phase 2b) is not expected until the first half of 2027, indicating a long-term timeline for any material benefit. The language is optimistic and aspirational, but the lack of disclosed trial results or financial data means the narrative is more promotional than evidentiary. There is no indication of a large capital outlay in this specific release, so the capital intensity flag is false. Overall, the gap between narrative and evidence is moderate, with the signal supported by milestone progress but not by hard data.

Risk flags

• ●The absence of quantitative safety and efficacy data from the Phase 1b trial leaves investors unable to independently assess the clinical merit of PH-762, increasing the risk that the program's value is overstated relative to actual results.
• ●The timeline to the next material catalyst is extended, with the Phase 2b trial not planned until the first half of 2027, creating prolonged uncertainty and execution risk around trial initiation, enrollment, and eventual outcomes.
• ●The company's narrative relies heavily on forward-looking statements and potential benefits without evidentiary support, raising the risk of narrative inflation and investor disappointment if future data do not align with current claims.

Bottom line

Phio Pharmaceuticals' update signals that PH-762 has advanced through Phase 1b and is being positioned as a potentially differentiated therapy for skin cancers, but the lack of disclosed trial data means investors have no basis to judge efficacy or safety. All claims of clinical benefit, tolerability, and tissue-sparing effects are unsubstantiated in this release, and the only concrete next step is a Phase 2b study planned for the first half of 2027. The long gap until the next milestone, combined with the absence of quantitative results, makes this announcement more promotional than actionable. Investors should recognize that the program remains early-stage, with significant clinical and execution risks ahead. The most important takeaway is that no new evidence has been provided to change the risk/reward profile of PH-762 at this time.

Announcement summary

(NASDAQ:PHIO) Phio Pharmaceuticals Corp. announced that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS), held from November 5-8, 2026. The presentation focused on the company's lead clinical development program, PH-762, an INTASYL compound designed to silence the PD-1 gene implicated in various forms of skin cancer. Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals, stated that the growing body of clinical evidence supports PH-762's potential to address an important unmet need in the treatment of cutaneous carcinomas. The e-presentation, titled 'Intasyl siRNA Compound PH-762', was delivered by John Strasswimmer, M.D., Ph.D., of Florida Atlantic University and Integrity Research at Dermatology Associates of the Palm Beaches, Inc., who served as the lead investigator of the Phase 1b clinical trial. The presentation included final results from the first Phase 1b study assessing the safety and efficacy of INTASYL PH-762 as a neoadjuvant intratumoral injection for cutaneous carcinomas. Study findings suggested that PH-762 is well-tolerated and may serve as a tissue-sparing neoadjuvant to the current cSCC treatment standard of Mohs micrographic surgery (MMS) and/or standard excision. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is positioned as a potential non-surgical treatment for skin cancers. Additional studies are needed to further evaluate the safety and efficacy of PH-762. A Phase 2b study is planned for the first half of 2027. The company’s INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. The company highlighted that PH-762 may shrink tumors before surgery, reduce the extent of resection, and ultimately improve patient outcomes. The company’s website is www.phiopharma.com.

Disagree with this article?